Targeted triple-combination treatment for children with relapsed blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 1 to 18 years old at the time of first diagnosis (and under 21 at study entry).
- Your child must have a good general condition (Lansky or Karnofsky score of at least 50%).
- Your child must have had tumor testing done (molecular testing and flow-cytometry) before enrollment to look for specific cancer markers.
- The cancer must have specific genetic changes in the IL-7R/JAK-STAT pathway (such as certain CRLF2, EPOR, IL7R, JAK1/2/3, or related mutations/fusions).
- Your child must have adequate heart, liver, and kidney function and no dangerous heart rhythm findings on baseline tests.
- Your child (or parent/guardian) must be willing to follow study procedures, including pregnancy prevention rules if applicable, and avoid certain medicines/foods during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
This trial tests a combination of two targeted drugs (capivasertib and venetoclax) plus a steroid (dexamethasone) in children and young adults with blood cancers that have come back or not responded to treatment. The goal is to see if this drug combination is safe and works against the cancer.
This Phase 1 study tests venetoclax to treat certain high-risk blood cancers in children, teens, or young adults. It is designed to see if the drug can work safely for patients whose disease has returned or did not respond to prior treatment.
This trial studies a treatment approach for children and teens newly diagnosed with lymphoblastic lymphoma. It may help doctors choose therapies based on genetic risk information from lab testing done on tumor samples.
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
Hear when a new Acute Lymphoblastic Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.